SCHOTT Pharma Aligns Climate Actions with Paris Agreement Goals

SCHOTT Pharma, based in Mainz, Germany, has reiterated its commitment to aligning its climate actions with the Paris Agreement, aiming to limit global warming to 1.5°C. This announcement comes as the Science Based Targets initiative (SBTi) validated SCHOTT Group’s climate action roadmap and targets.

SCHOTT Pharma focuses on energy efficiency, green electricity, and technological innovation to reduce greenhouse gas (GHG) emissions. By 2030, the company aims to achieve climate-neutral operations for Scope 1 and Scope 2 GHG emissions. Additionally, the company plans to cut 27.5% of Scope 3 GHG emissions by 2030 through targeted initiatives.

SCHOTT Pharma is promoting low-emission manufacturing technologies and is already using 100% green electricity since 2021. Collaborating with suppliers, the company emphasizes sustainable packaging and annually assesses key suppliers' sustainability.